Addex Therapeutics to Release Full-Year 2022 Financial Results and Host Conference Call on March 30, 2023
28 March 2023 - 04:00PM
Geneva, Switzerland, March
28,
2023 – Addex
Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage
pharmaceutical company pioneering allosteric modulation-based drug
discovery and development, today announced that it will issue its
full-year 2022 financial results on Thursday, March 30, 2023. Tim
Dyer, CEO and Robert Lütjens, Head of Discovery – Biology, will
provide a business update and a review of the Addex product
pipeline during a teleconference and webcast for investors,
analysts and media at 16:00 CEST (15:00 BST / 10:00 EDT / 07:00
PDT) the same day.
Title: Addex Therapeutics to
Announce Full Year 2022 Financial Results and Provides Corporate
Update Date: March 30, 2023Time: 16:00 CEST (15:00 BST / 10:00 EDT
/ 07:00 PDT)
Joining the Conference
Call:
- Participants are required to
register in advance of the conference using the link provided
below. Upon registering, each participant will be provided with
Participant Dial-in numbers, and a unique Personal PIN.
- In the 10 minutes prior to the call
start time, participants will need to use the conference access
information provided in the e-mail received at the point of
registering. Participants may also use the call me feature instead
of dialing the nearest dial in number.
Online Registration:
https://register.vevent.com/register/BI8f6a1aee693c405ebc85b10adfa18648
Webcast URL:
https://edge.media-server.com/mmc/p/7qb5zc3s
About Addex Therapeutics:Addex
Therapeutics is a clinical-stage pharmaceutical company focused on
the development and commercialization of an emerging class of novel
orally available, small molecule drugs known as allosteric
modulators for neurological disorders. Allosteric modulators offer
several potential advantages over conventional, non-allosteric
molecules and may offer an improved therapeutic approach to
conventional "orthosteric" small molecule or biological drugs.
Addex's allosteric modulator drug discovery platform targets
receptors and other proteins that are recognized as essential for
therapeutic intervention. Addex's lead drug candidate, ADX71149
(mGlu2 positive allosteric modulator or PAM), developed in
collaboration with Janssen Pharmaceuticals, Inc., is in a Phase 2a
proof of concept clinical trial for the treatment of epilepsy.
Addex's second clinical program, dipraglurant (mGlu5 negative
allosteric modulator or NAM), is under evaluation for future
development in a range of indications. Indivior PLC has licensed
Addex’s GABAB PAM program for the development of drug candidates,
with a focus on substance use disorder. Addex is also advancing a
broad preclinical pipeline, which includes development of a range
of GABAB PAMs for CMT1A, chronic cough and several types of pain,
mGlu7 NAM for stress related disorders, mGlu2 NAM for mild
neurocognitive disorders and depression, M4 PAM for
schizophrenia and other forms of psychosis, as well as mGlu4
PAM and mGlu3 PAM. Addex shares are listed on the SIX Swiss
Exchange and American Depositary Shares representing its shares are
listed on the NASDAQ Capital Market, and trade under the ticker
symbol "ADXN" on each exchange.
Press Contacts:
Tim DyerChief Executive OfficerTelephone: +41 22 884 15
55PR@addextherapeutics.com |
Mike SinclairPartner, Halsin Partners+44 (0)7968
022075msinclair@halsin.com |
Forward Looking Statements:This
press release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995, as
amended, including the ability to discover molecules as part of the
Indivior collaboration, the progress of clinical trials and
preclinical studies, including the timing of data read-outs from
the ADX71149 epilepsy study, and our intended strategic direction.
The words “may,” “will,” “could,” “would,” “should,” “expect,”
“plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,”
“project,” “potential,” “continue,” “target” and similar
expressions are intended to identify forward-looking statements,
although not all forward-looking statements contain these
identifying words. Any forward-looking statements in this press
release, such as receipt of ongoing research payments and timing of
the collaboration conclusion, are based on management's current
expectations and beliefs and are subject to a number of risks,
uncertainties and important factors that may cause actual events or
results to differ materially from those expressed or implied by any
forward-looking statements contained in this press release,
including, without limitation, uncertainties related to market
conditions. These and other risks and uncertainties are described
in greater detail in the section entitled “Risk Factors” in Addex
Therapeutics’ Annual Report on Form 20-F for the year ended
December 31, 2021, as filed with the SEC on March 10, 2022, the
prospectus supplement and accompanying prospectus and other filings
that Addex Therapeutics may make with the SEC in the future. Any
forward-looking statements contained in this press release
represent Addex Therapeutics’ views only as of the date hereof and
should not be relied upon as representing its views as of any
subsequent date. Addex Therapeutics explicitly disclaims any
obligation to update any forward-looking statements.
Addex Therapeutics (NASDAQ:ADXN)
Historical Stock Chart
From Mar 2024 to Mar 2024
Addex Therapeutics (NASDAQ:ADXN)
Historical Stock Chart
From Mar 2023 to Mar 2024